Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response

[1]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[2]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[3]  S. Rajkumar,et al.  Interpretation of cytogenetic results in multiple myeloma for clinical practice , 2015, Blood Cancer Journal.

[4]  S. Rajkumar,et al.  Guidelines for determination of the number of prior lines of therapy in multiple myeloma. , 2015, Blood.

[5]  M. Kersten,et al.  Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. , 2015, Blood.

[6]  E. Grove,et al.  A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. , 2014, Thrombosis research.

[7]  B. Pégourié,et al.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Esseltine,et al.  Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Therneau,et al.  Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma , 2013, Leukemia.

[10]  M. Kaminski,et al.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. , 2012, Blood.

[11]  Lust,et al.  Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. , 2012, Blood.

[12]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[13]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[14]  B. Grosbois,et al.  Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials , 2007, Leukemia.

[15]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[16]  P. L. Bergsagel,et al.  A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy , 2007, Leukemia.

[17]  G. Ahmann,et al.  Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.

[18]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[19]  J. Soulier,et al.  Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases , 2003, Genes, chromosomes & cancer.

[20]  P. Moreau,et al.  t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma , 2003, Leukemia.

[21]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[22]  R. Bataille,et al.  Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. , 2003, Blood.

[23]  G. Ahmann,et al.  Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.

[24]  R. Fonseca,et al.  Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. , 2002, Blood.

[25]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.

[26]  D. Harrington,et al.  Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. , 2002, Cancer research.

[27]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[28]  Manpreet Singh,et al.  Workshop Report , 2005, IPTPS.

[29]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.